Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O15204
UPID:
ADEC1_HUMAN
Alternative names:
A disintegrin and metalloproteinase domain-like protein decysin-1
Alternative UPACC:
O15204; B7ZAK5
Background:
ADAM DEC1, also known as A disintegrin and metalloproteinase domain-like protein decysin-1, is a protein that may play a pivotal role in immune response regulation and during pregnancy. Its unique structure and function suggest a significant role in biological processes, contributing to the maintenance of immune homeostasis and fetal-maternal tolerance.
Therapeutic significance:
Understanding the role of ADAM DEC1 could open doors to potential therapeutic strategies. Its involvement in immune regulation and pregnancy suggests that targeting ADAM DEC1 could offer novel approaches in treating immune-related disorders and improving pregnancy outcomes.